niacinamide has been researched along with Cardiotoxicity in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is associated with adverse cardiac effects, including left ventricular dysfunction." | 7.81 | Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. ( Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B, 2015) |
| " The underlying mechanism of these adverse cardiac effects is largely unknown." | 5.51 | Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. ( Becker, JR; Force, T; Galindo, CL; Glennon, MS; Gupte, M; Lal, H; Singh, AP; Umbarkar, P; Zhang, Q, 2019) |
| " However, the use of some SMKIs, such as sorafenib (SO), has been plagued by their cardiotoxicity that has been frequently observed in treated patients." | 3.85 | Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor. ( Bardelang, D; Huang, Q; Lee, SMY; Wang, C; Wang, R; Yang, X, 2017) |
| "Sorafenib is associated with adverse cardiac effects, including left ventricular dysfunction." | 3.81 | Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. ( Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B, 2015) |
| " The underlying mechanism of these adverse cardiac effects is largely unknown." | 1.51 | Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. ( Becker, JR; Force, T; Galindo, CL; Glennon, MS; Gupte, M; Lal, H; Singh, AP; Umbarkar, P; Zhang, Q, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Podyacheva, E | 1 |
| Toropova, Y | 1 |
| Zou, L | 1 |
| Liang, B | 1 |
| Gao, Y | 1 |
| Ye, T | 1 |
| Li, M | 1 |
| Zhang, Y | 2 |
| Lu, Q | 1 |
| Hu, X | 1 |
| Li, H | 1 |
| Yuan, Y | 1 |
| Xing, D | 1 |
| Hua, H | 1 |
| Zhao, Q | 1 |
| Xia, J | 1 |
| Dai, QL | 1 |
| Bai, SR | 1 |
| Wang, XB | 1 |
| Zhou, M | 1 |
| Yang, X | 1 |
| Huang, Q | 1 |
| Bardelang, D | 1 |
| Wang, C | 1 |
| Lee, SMY | 1 |
| Wang, R | 1 |
| Stuhlmiller, TJ | 1 |
| Zawistowski, JS | 1 |
| Chen, X | 1 |
| Sciaky, N | 1 |
| Angus, SP | 1 |
| Hicks, ST | 1 |
| Parry, TL | 1 |
| Huang, W | 1 |
| Beak, JY | 1 |
| Willis, MS | 1 |
| Johnson, GL | 1 |
| Jensen, BC | 1 |
| Singh, AP | 1 |
| Glennon, MS | 1 |
| Umbarkar, P | 1 |
| Gupte, M | 1 |
| Galindo, CL | 1 |
| Zhang, Q | 1 |
| Force, T | 1 |
| Becker, JR | 1 |
| Lal, H | 1 |
| Zheng, D | 1 |
| Zheng, M | 1 |
| Cao, T | 1 |
| Wang, G | 1 |
| Zhang, L | 1 |
| Ni, R | 1 |
| Brockman, J | 1 |
| Zhong, H | 1 |
| Fan, GC | 1 |
| Peng, T | 1 |
| Kawabata, M | 1 |
| Umemoto, N | 1 |
| Shimada, Y | 1 |
| Nishimura, Y | 1 |
| Zhang, B | 1 |
| Kuroyanagi, J | 1 |
| Miyabe, M | 1 |
| Tanaka, T | 1 |
| Abdel-Rahman, O | 1 |
| Fouad, M | 1 |
3 reviews available for niacinamide and Cardiotoxicity
| Article | Year |
|---|---|
Nicotinamide Riboside for the Prevention and Treatment of Doxorubicin Cardiomyopathy. Opportunities and Prospects.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxici | 2021 |
Nicotinic Acid Riboside Regulates Nrf-2/P62-Related Oxidative Stress and Autophagy to Attenuate Doxorubicin-Induced Cardiomyocyte Injury.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cardiotonic Agents; Cardiotoxicity; Dexrazoxan | 2022 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; | 2014 |
6 other studies available for niacinamide and Cardiotoxicity
| Article | Year |
|---|---|
Peficitinib ameliorates doxorubicin-induced cardiotoxicity by suppressing cellular senescence and enhances its antitumor activity.
Topics: Animals; Apoptosis; Cardiotoxicity; Cellular Senescence; Doxorubicin; Humans; Mice; Myocytes, Cardia | 2023 |
Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cardiotoxicity; Cell Line, Tumor; Cell Survi | 2017 |
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; E | 2017 |
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Apoptosis; Cardiotoxicity; Cells, Cul | 2019 |
Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Autophagy; Cardiotoxicity; Cells, Cultured; Cytoprotection; Disease Models, A | 2019 |
Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
Topics: Adult; Animals; Antineoplastic Agents; Cardiotoxicity; Down-Regulation; Glycoproteins; Heart; Humans | 2015 |